Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: A prospective randomized trial

World Journal of Surgery

Volumn 37, Issue 6, 2013, Pages 1356-1361

  Chung, A Y F ^a   Ooi, L L P J ^b   Machin, D ^c   Tan, S B ^c,f   Goh, B K P ^a   Wong, J S ^a   Chen, Y M ^c   Li, P C N ^c   Gandhi, M ^c,f   Thng, C H ^b   Yu, S W K ^a   Tan, B S ^a   Lo, R H G ^a   Htoo, A M M ^a   Tay, K H ^a,e   Sundram, F X ^a   Goh, A S W ^a   Chew, S P ^d   Liau, K H ^d   Chow, P K H ^a   Tan, Y M ^b   Cheow, P C ^a   Ho, C K ^d   Soo, K C ^b   more..

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e CHANGI GENERAL HOSPITAL   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETHIODIZED OIL; RADIOACTIVE IODINE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; LIVER NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; ETHIODIZED OIL; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84877748411     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-1970-4     Document Type: Review

References (22)

1. Parkin DM, Whelan SL, Ferlay J et al (2002) Cancer incidence in five continents, vol VIII. IARC Scientific, Lyon publication no. 155
2. Parfitt JR, Marotta P, Alghamdi M et al (2007) Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transplant 13:543-551
3. Shah A, Cleary SP, Wei AC et al (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141:330-339
4. Tanaka S, Noguchi N, Ochiai T et al (2007) Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting Milan criteria: rationale for partial hepatectomy as first strategy. J Am Coll Surg 204:1-6
5. Lau WY (2002) Management of hepatocellular carcinoma. J R Coll Surg Edinb 47:389-399
6. Matsuda Y, Ito I, Oguchi Y et al (1993) Rationale of surgical management for recurrent hepatocellular carcinoma. Ann Surg 217:28-34
7. Schwartz JD, Schwartz M, Mandeli J et al (2002) Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized trials. Lancet Oncol 3:593-603
8. Samuel M, Chow PK, Chan Shih-Yen E et al. (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev (1):CD001199
9. Lau WY, Leung TW, Ho SK et al (1999) Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 353:797-801
10. Pocock S, White I (1999) Trials stopped early: too good to be true? Lancet 353:943-944
11. Machin D, Campbell MJ, Fayers PM et al (1997) Statistical tables for the design of clinical studies. Blackwell Scientific, Oxford
12. Madsen MT, Park CH, Thakur ML (1988) Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 29:1038-1044
13. Snyder WS, Ford MR, Warner GG et al (1975) MIRD pamphlet #11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs (part 1). Society of Nuclear Medicine, Reston
14. Snyder WS, Ford MR, Warner GG et al (1975) MIRD pamphlet #11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs (part 2). Society of Nuclear Medicine, Reston
15. Snyder WS, Ford MR, Warner GG et al (1975) MIRD pamphlet #11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs (part 3). Society of Nuclear Medicine, Reston
16. Lau WY, Lai EC, Leung TW et al (2008) Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma, a prospective randomized trial - update on 5-year and 10-year survival. Ann Surg 247:43-48
17. Boucher E, Corbinais S, Rolland Y et al (2003) Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237-1241
18. Tabone M, Vigano L, Ferrero A et al (2007) Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 33:61-66
19. Poon RT, Fan ST, Ng IO et al (2000) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231:544-551
20. Poon RT, Fan ST, Wong J (2000) Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10-24
21. Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and slow phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200-207
22. Poon RT, Fan ST, Ng IO et al (2000) Different risk factors and prognosis for early and slow intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500-507